Company Overview - Kenvue, the maker of Tylenol, experienced a significant stock fluctuation, dropping 7.5% on Monday following comments from President Trump, but rebounded by over 6% at the opening of trading on Tuesday [3][8] - Kenvue was spun off from Johnson & Johnson in 2023 to enhance operational efficiency, and it produces various consumer health products including Band-Aids and Listerine [6] Industry Context - President Trump's remarks linked Tylenol to autism, which Kenvue strongly disputed, emphasizing the importance of the drug for pregnant women facing health risks [5][8] - The announcement by Trump was based on existing studies rather than new research, and it coincided with the activities of Health and Human Services Secretary Robert F. Kennedy Jr., a known vaccine skeptic [4][8] Market Reaction - Analysts, including Citi Investment Research's Filippo Falorni, noted a limited risk of new lawsuits but acknowledged potential negative impacts on Tylenol consumption due to the adverse publicity [8] - Despite the controversy, the lack of new scientific evidence is expected to lead to a positive market reaction for Kenvue's stock [8]